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Abstract
Background: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments
beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most
common treatments used among specialists and assess their interest in newer therapies.
Methods: An international survey was distributed to dry eye researchers and expert practitioners via an internet
survey. The survey data collected were analyzed with descriptive statistics.
Results: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The
most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone
(FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97,
49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104,
69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs
(76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by
less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months
(24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein
staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation.
Conclusion: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey
are hypothesis generating and will aid in the design of future clinical studies.
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Background
DED results from reduced tear production or excessive
tear evaporation and is estimated to affect 1,000 000 to
4.9,000 000 people in the United States, primarily in eld-
erly and female populations [1]. Symptoms of burning
and tearing can cause a significant reduction in quality
of life for patients. In severe cases, they may develop
complications such as corneal scarring, bacterial kera-
titis, and vision loss [1, 2].
DED is divided by etiology into two categories: aque-
ous deficient (keratoconjunctivitis sicca) and evaporative
disorders. Treatment of aqueous deficient DED has
traditionally started with artificial tears and topical lubri-
cants [3]. Topical anti-inflammatory medications, in-
cluding corticosteroids and cyclosporine A 0.05 %, are
commonly used for more moderate to severe cases [3].
Although not fully understood, ocular surface damage
from either disorder may incite an inflammatory re-
sponse that further worsens DED [4]. This has inspired
many studies exploring new anti-inflammatory treatments
for both aqueous deficient and evaporative DED, including
topical tacrolimus, topical autologous serum, oral tetracy-
clines and omega fatty acid supplements [5–8].
In this study, we conduct an international survey of
dry eye experts to identify the most common treatments
used for aqueous deficient DED beyond traditional ther-
apies such as preservative free artificial tears (PFATs).
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Methods
A survey was distributed to researchers and expert prac-
titioners in the field of DED via the internet survey tool
SurveyMonkey (surveymonkey.com, LLC; Palo Alto,
California) in April 2013. Experts were identified by col-
lecting corresponding author information from recently
published manuscripts in the field of dry eye. PubMed
and Web of Science were queried using the search terms
“sjögren eye,” “keratoconjunctivitis sicca,” and “dry eye,”
and all articles published from November 2008 to
November 2012 were included. Those who had previ-
ously opted out of receiving emails from SurveyMonkey
or those with invalid email addresses were pre-
determined to be ineligible. The survey was anonymous
and no participant identifiers of name, gender or age
were collected; all recipients had the option of participat-
ing or opting out. IRB exemption was obtained from the
University of California, San Francisco Committee on
Human Research. The study adhered to the Declaration of
Helsinki and all federal and state laws. After its initial dis-
tribution in April 2013, two survey reminders were sent
and the survey was closed on July 1, 2013.
The survey consisted of 11 questions (Appendix 1),
which were developed after a literature search identified
the most common available medications for DED. Sur-
vey recipients were first presented with a clinical sce-
nario of a patient with symptoms and physical exam
findings consistent with aqueous deficient DED. Respon-
dents were then asked to describe their use of various
therapies for this patient including punctal plugs, topical,
and oral medications using Likert scales. Next, partici-
pants were asked to indicate which of these therapies
they would be interested in using more and primary lim-
itations to their current use. Respondents were ques-
tioned regarding their routine treatment algorithms and
treatment milestones they use to guide therapy. Lastly,
general demographic questions were asked. Descriptive
statistical analyses were performed using Stata 10.0
(StataCorp, College Station, TX).
Results
A literature search identified 1450 unique email addresses.
Of these, 111 email addresses had previously opted out of
SurveyMonkey; subsequently, the survey was sent to 1339
recipients. A total of 115 (8.6 %) recipients completed the
survey. The majority identified themselves as cornea spe-
cialists (66 %); the remaining respondents were compre-
hensive ophthalmologists (16 %), non-clinical researchers
(6 %), optometrists (6 %) and other (6 %). Most respon-
dents reported treating over 60 aqueous deficient dry eye
patients in the last year (76 %). For clinicians reporting
duration of practice, the average number of years in clin-
ical practice was 16.5 years (median 13, range 3–40 years).
Respondents were primarily from Europe (35 %) and the
United States/Canada (28 %); others were from Asia/
Indian subcontinent, Central and South America,
Australia/New Zealand, the Middle East and Africa.
The most commonly prescribed topical treatments
(defined as responses of use always, frequently or some-
times) for aqueous deficient DED include cyclosporine A
(CSA) 0.05 % (71/104, 68 %), fluorometholone (FML)
0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99,
51 %), and autologous serum eye drops (ASD; 48/97,
49 %) (Table 1). Respondents reported improvement
with CSA treatment between 2 weeks and 2 months (45/
85, 53 %) followed by 2 to 6 months (24/85, 28 %). Only
2 respondents indicated improvements with cyclosporine
treatment at 6 months and longer. When asked how
long respondents treated patients with topical corticoste-
roids (including the taper period), most reported 2 to
8 weeks (46/86, 53 %), followed by less than 2 weeks
(24/86, 28 %).
Table 1 Respondents’ use of various topical medications for patients with clinical scenario consistent with aqueous deficient DED
(artificial tears excluded)
Topical Medications Never use Rarely use Sometimes Frequently Always use
N (%) N (%) N (%) N (%) N (%)
Cyclosporine A, 0.05 %, ophthalmic emulsion (RESTASIS) (N = 105) 22 (21) 12 (11) 21 (20) 35 (33) 15 (14)
Cyclosporine A, 0.1 %, ophthalmic emulsion (N = 93) 49 (53) 22 (24) 15 (16) 6 (6) 1 (1)
diclofenac sodium 0.1 % (N = 97) 63 (65) 21 (22) 12 (12) 1 (1) 0 (0)
prednisolone acetate 1 % (N = 96) 39 (41) 28 (29) 20 (21) 9 (9) 0 (0)
fluorometholone 0.1 % (N = 99) 22 (22) 18 (18) 34 (35) 23 (23) 2 (2)
Loteprednol etabonate 0.5 % (N = 99) 28 (28) 21 (21) 18 (18) 29 (30) 3 (3)
Resolvin E1 (omega −3 FA) eye drop (N = 95) 64 (67) 7 (8) 20 (21) 4 (4) 0 (0)
Diquafosol 3 % ophthalmic solution (N = 93) 75 (81) 10 (11) 5 (5) 3 (3) 0 (0)
Tacrolimus 0.03 % ophthalmic emulsion (N = 94) 60 (64) 25 (27) 7 (7) 1 (1) 1 (1)
Autologous serum eye drops (N = 97) 30 (31) 19 (19.5) 27 (28) 19 (19.5) 2 (2)
Vitamin A eye drops (0.01 % all trans-retinoic acid) (N = 96) 39 (41) 27 (28) 22 (23) 7 (7) 1 (1)
Sy et al. BMC Ophthalmology  (2015) 15:133 Page 2 of 6
The most commonly prescribed oral medications
(defined as use always, frequently or sometimes) included
essential fatty acid supplements (72/104, 69 %), low-dose
doxycycline (oral; 61/100, 61 %), and flaxseed supplements
(32/96, 33 %) (Table 2). Punctal plugs were commonly
used as well (76/102, 75 %; Table 2).
Respondents reported wanting to prescribe cyclospor-
ine A 0.05 % (52/79, 66 %), autologous serum eye drops
(39/73, 53 %), resolvin E1 (omega 3 fatty acid) eye drops
(31/72, 43 %), and diquafosol 3 % (31/75, 41 %) more
often. Of those who indicated they would use cyclospor-
ine A 0.05 % and autologous serum eye drops more, the
most cited reason for not being able to prescribe these
medications currently was high cost or lack of insurance
coverage. The primary reason for not being able to pre-
scribe resolvin E1 eye drops and diquafosol 3 % was dif-
ficulty obtaining the medication, although respondents
also indicated an interest in more research supporting
the use of resolvin E1 drops. There was also moderate
interest in cyclosporine A 1 % (28/72, 39 %), vitamin A
eye drops 0.01 % (30/77, 39 %), and tacrolimus 0.03 %
(25/73, 34 %). The most cited reasons for not being able
to prescribe these medications was availability of cyclo-
sporine A 1 % and vitamin A eye drops, and insufficient
data to support tacrolimus use.
Regarding alternatives to topical therapy, study par-
ticipants indicated they would be most interested in
using essential fatty acids (EFA) (34/77, 44 %), punctal
plugs (31/77, 40 %) and low-dose doxycycline (25/69,
36 %). About half of the participants cited cost as a
limiting factor for use of EFA, while the other half
cited insufficient research data to support its use.
Cost was also the primary prohibitive factor for punc-
tal plugs. For those interested in using doxycycline,
respondents listed “other” reasons as the limiting fac-
tor. Participants also expressed interest in more
investigation into essential fatty acids, rituximab and
dehydroepiandrosterone (DHEA).
The top three signs and symptoms reported to indicate
treatment response were, in order, fluorescein staining of
the cornea, reduction in foreign body sensation, and re-
duction in burning sensation, together accounting for
over 53 % of the responses (134/255). The remaining
outcomes were, in order: tear break-up time, improved
tear production, lissamine green staining, Schirmer type
1 (no anesthetic), and rose-bengal staining.
Discussion
The goal of this survey was to characterize the most
commonly prescribed treatments for aqueous deficient
DED among dry eye specialists and to identify thera-
peutic options that may be of interest for future study.
Our results indicate that while many ophthalmologists
are commonly using topical therapies such as steroids
and cyclosporine A 0.05 %, they are also turning to oral
and other non-topical therapies.
Among topical therapies for aqueous-deficient DED,
respondents were most commonly using topical steroids
(fluorometholone 0.1 % and loteprednol etabonate
0.5 %), CSA 0.05 %, and autologous serum eye drops.
While these practice patterns may reflect respondent ex-
perience and interpretation of clinical data, they are also
likely affected by local drug availability. The role of in-
flammation in DED makes topical corticosteroids a nat-
ural candidate for therapy, but significant side effects
with prolonged corticosteroid therapy, including second-
ary glaucoma, infection and cataract formation, have
limited their use. One randomized controlled trial found
loteprednol etabonate 0.5 % to be effective over placebo
in patients with moderate clinical inflammation [9].
Topical CSA is an attractive alternative given its relative
safety. In addition, it is the only medication approved by
Table 2 Respondents’ use of various non-topical medications for patient with clinical scenario consistent with aqueous deficient
DED
Non-topical medications Never use Rarely use Sometimes Frequently Always use
N (%) N (%) N (%) N (%) N (%)
Essential Fatty Acids (omega-3 fatty acid, linolenic acid) supplements (N = 104) 15 (14) 17 (16) 29 (28) 31 (30) 12 (12)
Flaxseed supplements (N = 96) 42 (44) 22 (23) 14 (14) 15 (16) 3 (2)
Doxycycline, low dose, oral (N = 100) 18 (18) 21 (21) 35 (35) 25 (25) 1 (1)
Pilocarpine, oral (N = 98) 62 (63) 24 (25) 7 (7) 3 (3) 2 (2)
Cevimeline, oral (N = 96) 72 (75) 16 (17) 5 (5) 2 (2) 1 (1)
Hydroxychloroquine 6-7 mg/kg daily (N = 97) 74 (76) 17 (18) 5 (5) 1 (1) 0 (0)
Rituximab (N = 97) 82 (85) 13 (13) 2 (2) 0 (0) 0 (0)
Cyclosporine, oral (N = 99) 82 (83) 14 (14) 2 (2) 1 (1) 0 (0)
Corticosteroids, oral (N = 98) 72 (73) 21 (21) 3 (3) 2 (2) 0 (0)
Dehydroepiandrosterone (DHEA), oral (N = 98) 85 (87) 9 (9) 3 (3) 0 (0) 1 (1)
Punctal Plugging (N = 102) 10 (10) 16 (16) 39 (38) 33 (32) 4 (4)
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the US Food and Drug Administration for moderate to
severe DED, and has been well studied in clinical trials
[10–12]. These clinical trials also studied the use of CSA
0.1 %, and many found it to be as efficacious as the
0.05 % formulation as well as safe in both short and long
term studies [11, 12]. Respondents in this survey demon-
strated an interest in using a stronger formulation of
CSA (0.1 %), but are prohibited by its lack of availability.
Compounding pharmacies are required to obtain CSA
0.1 % as commercial formulation is undergoing regula-
tory review in Europe. The optimal duration of therapy
with topical CSA is unclear. One study has suggested
that after a year of standard twice daily CSA 0.05 % ther-
apy, patients can be successfully weaned to once daily
therapy without significant worsening of their symp-
toms. [13] Respondents of this survey reported most
commonly seeing improvements with CSA therapy in
shorter time periods (2 weeks to 2 months). ASD are
thought to alleviate dry eye by supplying tear components
such as various growth factors and vitamins that aid in the
maintenance of the ocular surface; it has been studied
in a handful of small clinical studies, the majority of which
have found it to be more effective than artificial tears
[7, 14–17]. However, there have not been studies
comparing ASD to other medications such as CSA.
While CSA, topical corticosteroid and ASD appear to
have been accepted into the community practice, there is
a lack of comparative studies between these agents.
Among non-topical therapies for DED patients, re-
spondents were most commonly using punctal plugs,
oral EFA supplements, low-dose oral doxycycline and
flaxseed supplements. Punctal plugs have been studied
in multiple clinical trials, and a recent Cochrane review
found that although the literature did not decisively sup-
port its efficacy for dry eye treatment, the data did sug-
gest “usefulness” in DED [18]. EFA supplements are
traditionally used to treat evaporative DED or meibo-
mian gland disease. Systemic EFA supplements have
been studied in small- to moderate-sized clinical trials;
only a few showed improvements for limited measures
of DED, with others finding no statistically significant
improvement [19–22]. Doxycycline, an antibacterial with
anti-inflammatory effects, gained traction as a therapy
for DED when inflammatory pathways were added to
the understanding of dry eye pathogenesis [5]. It has
primarily been studied in ocular rosacea, but a recent
study in a small number of patients suggests doxycyc-
line to be effective in restoring tear film stability in dry
eye patients [23–26]. Despite limited data for both
omega fatty acids and doxycycline, both are being used
by survey respondents, with significant interest in in-
creasing their use.
Study participants reported significant interest in new
topical therapies, particularly diquafosol and vitamin A
eye drops. Diquafosol (1–3 %), a P2Y2 receptor agonist
thought to promote non-glandular secretion of fluid, is
available primarily in East Asian countries due to its ap-
proval for use in Japan, but is still undergoing clinical re-
view in the United States. Survey respondents from the
Asian/Indian subcontinent did not demonstrate a higher
frequency of diquafosol use. Diquafosol has been found
in a number of prospective clinical trials to be effective
compared with placebo and sodium hyaluronate; there
have been no studies comparing its efficacy to CSA
0.05 % [27–30]. Vitamin A has been identified in natural
tears and vitamin A deficiency is thought to cause evap-
orative DED. Vitamin A drops have been shown in one
moderate-sized trial to significantly improve dry eye
signs and symptoms over artificial tears, and had similar
efficacy to CSA 0.05 % [31]. Respondents also demon-
strated interest in two lesser studied medications: topical
tacrolimus and resolvin E1 (EFA) eye drops, and appro-
priately called for more clinical investigations into these
medications. Tacrolimus 0.03 %, a macrolide with immu-
nomodulatory properties, was found in small prospective
case series to significantly improve signs of dry eye in
Sjogren’s syndrome patients and in graft versus host dis-
ease patients refractory to topical CSA 0.05 %; it has yet to
be studied in a randomized controlled trial setting [6, 32].
A stronger formulation of tacrolimus (0.1 %) has been
approved in Japan and is readily available in East
Asian countries, though survey respondents from
Asia/Indian sub-continent did not report using this
treatment more frequently. Resolvin and other topical
EFA formulations have only been studied in animal
models [33, 34]. While lack of availability was a sig-
nificant barrier to respondents using all 4 topical
therapies, use of vitamin A drops, tacrolimus and
topical EFA was also limited by lack of clinical data.
Our results suggest non-topical therapies, such as ri-
tuximab and DHEA, are of great interest to clinicians as
targets for future research in the treatment of aqueous
deficient DED. Rituximab has been reported in case re-
ports for keratoconjunctivitis sicca, but has mostly been
studied in clinical trials for primary Sjogren’s. Results are
pending from two recent clinical trials, the Tolerance
and Efficacy of Rituximab in Sjogren’s Disease trial
and the Trial of Anti-B-Cell Therapy in Patients With
Primary Sjögren’s Syndrome [35–39]. Minimal litera-
ture exists for the use of sex steroids, such as DHEA,
in DED. DHEA supplementation has been studied in
Sjogren’s syndrome and has not had promising results
[40, 41]. Interestingly, respondents were not interested
in cholinerigic agonists such as pilocarpine and cevi-
meline which have been shown in clinical trials to be
effective for dry eye secondary to Sjogren’s syndrome;
there was also little interest in hydroxychloroquine,
oral cyclosporine or oral steroids [8].
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One issue in studying DED is the lack of consensus re-
garding measures of efficacy in clinical trials. This is
compounded by the fact that severity of symptoms do
not correlate with exam findings [42]. Outcomes of
interest to clinicians in this survey were fluorescein
staining of the cornea, reduction in foreign body sensa-
tion and reduction in burning sensation. Interestingly,
Schirmer type 1 test was not among the top responses
despite commonly being used clinically and in clinical
trials [42]. The results of this survey may guide the se-
lection of outcomes in future clinical trials.
Limitations of this study include those intrinsic to all
surveys, including recall bias and non-response bias.
The response rate of 8.6 % is not uncommon and is bet-
ter than previous dry eye surveys [43, 44]. A strength of
the survey is the high proportion of respondents who
were corneal specialists, as this is likely to be the popu-
lation most interested in the topic. Our method of sur-
veying biases toward academic practitioners, and
therefore likely represents expert opinion rather than
current practices in general. Since the survey did not in-
clude traditional therapies such as PFATs, this increased
the responses to other therapies such as ASD, which
likely does not reflect current practice outside of aca-
demic centers. However, this survey is informative about
the implementation of newer treatments in DED and is
hypothesis generating for future areas of study. The sur-
vey could not address all possible potential therapies,
which may have prohibited the identification of other
treatments of interest. Respondents were given the op-
tion to suggest additional therapies, but responses were
minimal. Finally, as respondents practice patterns are
likely limited by drug availability and local treatment
guidelines, the geographic diversity of respondents is a
strength of the survey.
Conclusions
The need for alternative, more effective DED treatments
is clear. By determining current practice patterns, this
survey offers insight into alternative therapies that are
already being used amongst practitioners. Additionally,
the results of this survey identify therapies of interest
and important clinical outcomes that can aid in the de-
velopment of future clinical studies.
Consent
Informed consent was obtained from all study partici-
pants for the publication of this report.
Abbreviations
DED: Dry eye disease; CSA: Cyclosporine A; FML: Fluorometholone;
ASD: Autologous serum drops; PFATs: Preservative free artificial tears;
EFA: Essential fatty acids; DHEA: Dehydroepiandrosterone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AS participated in the design and coordination of the study, survey
distribution and data gathering, statistical analysis and drafting of the
manuscript. KSO participated in the design of the study, survey distribution
and statistical analysis. MPL participated in interpretation of data and revision
of manuscript. PAC participated in coordination of the study and revision of
manuscript. NRA participated in study conception and design and
interpretation of data. TML participated in study conception and design,
statistical analysis, data interpretation and draft of the manuscript. JRN
participated in study coordination, data interpretation and revision of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank the Proctor Foundation (AS, KSO, PAC, NRA,
TML, JRN) and the Pacific Vision Foundation (AS, MPL) for their generous
support. These organizations had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Author details
1Department of Ophthalmology, California Pacific Medical Center, San
Francisco, CA, USA. 2F.I. Proctor Foundation, University of California, Room
S309, 513 Parnassus Ave, UCSF, San Francisco, CA 94143-0412, USA.
3Department of Ophthalmology, University of California, San Francisco, CA,
USA.
Received: 28 January 2015 Accepted: 30 September 2015
References
1. The epidemiology of dry eye disease: report of the Epidemiology
Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf.
2007;5:93–107.
2. Um SB, Kim NH, Lee HK, Song JS, Kim HC. Spatial epidemiology of dry eye
disease: findings from South Korea. Int J Health Geogr. 2014;13:31.
3. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al.
Clinical guidelines for management of dry eye associated with Sjogren
disease. Ocul Surf, 2015;13(2):118–32.
4. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated
ocular surface disorder. Arch Ophthalmol. 2012;130:90–100.
5. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol.
2004;137:337–42.
6. Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY.
Clinical treatment of dry eye using 0.03 % tacrolimus eye drops. Cornea.
2012;31:945–9.
7. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al.
Comparison of autologous serum eye drops with conventional therapy in a
randomised controlled crossover trial for ocular surface disease. Br J
Ophthalmol. 2004;88:647–52.
8. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ.
Treatment of Sjogren’s syndrome-associated dry eye an evidence-based
review. Ophthalmology. 2011;118:1242–52.
9. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS,
et al. A randomized, double-masked, placebo-controlled, multicenter
comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and
placebo for treatment of keratoconjunctivitis sicca in patients with delayed
tear clearance. Am J Ophthalmol. 2004;138:444–57.
10. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A
ophthalmic emulsion in the treatment of moderate-to-severe dry eye
disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study
Group. Ophthalmology. 2000;107:967–74.
11. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized
studies of the efficacy and safety of cyclosporine ophthalmic emulsion in
moderate to severe dry eye disease. CsA Phase 3 Study Group.
Ophthalmology. 2000;107:631–9.
12. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of
cyclosporine 0.1 % ophthalmic emulsion administered twice daily to dry
eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790–4.
13. Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of
cyclosporine A 0.05 % on dry eye disease after 1 year of twice-daily therapy.
Cornea. 2011;30:1098–104.
Sy et al. BMC Ophthalmology  (2015) 15:133 Page 5 of 6
14. Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized
double-blind clinical trial of autologous serum versus artificial tears in dry
eye syndrome. Curr Eye Res. 2012;37:684–8.
15. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M et al. The effect of
autologous serum eyedrops in the treatment of severe dry eye disease: a
prospective randomized case–control study. Am J Ophthalmol. 2005;139:242–6.
16. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ et al.
Controlled study of the use of autologous serum in dry eye patients.
Cornea. 2001;20:802–6.
17. Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops
for severe dry eye syndrome: a randomized double-blind crossover study.
Graefes Arch Clin Exp Ophthalmol. 2014;252:619–26.
18. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye
syndrome. The Cochrane database of systematic reviews. 2010(9):CD006775.
19. Wojtowicz JC, Butovich I, Uchiyama E, Aronowicz J, Agee S, McCulley JP.
Pilot, prospective, randomized, double-masked, placebo-controlled clinical
trial of an omega-3 supplement for dry eye. Cornea. 2011;30:308–14.
20. Creuzot C, Passemard M, Viau S, Joffre C, Pouliquen P, Elena PP et al.
Improvement of dry eye symptoms with polyunsaturated fatty acids. J Fr
Ophtalmol. 2006;29:868–73.
21. Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, et al.
Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome
with an inflammatory component. Cornea. 2003;22:97–101.
22. Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6
essential fatty acid treatment and pge1 tear content in Sjogren’s syndrome
patients. Invest Ophthalmol Vis Sci. 2005;46:4474–9.
23. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral
doxycycline therapy of meibomian gland dysfunction: a comparative clinical
and spectroscopic pilot study. Cornea. 2013;32:44–53.
24. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and
tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92.
25. Bartholomew RS, Reid BJ, Cheesbrough MJ, Macdonald M, Galloway NR.
Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.
Br J Ophthalmol. 1982;66:386–8.
26. Seal DV, Wright P, Ficker L, Hagan K, Troski M, Menday P. Placebo controlled
trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and
rosacea. Br J Ophthalmol. 1995;79:42–5.
27. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al.
Double-masked, placebo-controlled safety and efficacy trial of diquafosol
tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Cornea. 2004;23:784–92.
28. Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic
Solution Phase 2 Study G. Efficacy and safety of diquafosol ophthalmic
solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Ophthalmology. 2012;119:1954–60.
29. Kamiya K, Nakanishi M, Ishii R, Kobashi H, Sato N, Shimizu K. Clinical
evaluation of the additive effect of diquafosol tetrasodium on sodium
hyaluronate monotherapy in patients with dry eye syndrome: a prospective,
randomized, multicenter study. Eye. 2012;26:1363–8.
30. Takamura E, Tsubota K, Watanabe H, Ohashi Y. Diquafosol Ophthalmic
Solution Phase 3 Study G. A randomised, double-masked comparison study
of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye
patients. Br J Ophthalmol. 2012;96:1310–5.
31. Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a
0.05 % eye drops for treatment of dry eye syndrome. Am J Ophthalmol.
2009;147:206–13. e3.
32. Sanz-Marco E, Udaondo P, Garcia-Delpech S, Vazquez A, Diaz-Llopis M.
Treatment of refractory dry eye associated with graft versus host disease
with 0.03 % tacrolimus eyedrops. J Ocul Pharmacol Ther. 2013;29:776–83.
33. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical
omega-3 and omega-6 fatty acids for treatment of dry eye. Arch
Ophthalmol. 2008;126:219–25.
34. de Paiva CS, Schwartz CE, Gjorstrup P, Pflugfelder SC. Resolvin E1 (RX-10001)
reduces corneal epithelial barrier disruption and protects against goblet cell
loss in a murine model of dry eye. Cornea. 2012;31:1299–303.
35. Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjogren keratoconjunctivitis
sicca treated with rituximab. Cornea. 2007;26:886–7.
36. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment
in primary Sjogren’s syndrome: a randomized, double-blind, placebo-
controlled trial. Arthritis Rheum. 2010;62:960–8.
37. Radford CF, Lehmann OJ, Dart JK. Acanthamoeba keratitis: multicentre
survey in England 1992–6. National Acanthamoeba Keratitis Study Group.
Br J Ophthalmol. 1998;82:1387–92.
38. Bacon AS, Frazer DG, Dart JK, Matheson M, Ficker LA, Wright P. A review of
72 consecutive cases of Acanthamoeba keratitis, 1984–1992. Eye (Lond).
1993;7(Pt 6):719–25.
39. Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J et al. The
TRACTISS protocol: a randomised double blind placebo controlled clinical
trial of anti-B-cell therapy in patients with primary Sjogren’s Syndrome. BMC
Musculoskelet Disord. 2014;15:21.
40. Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, et al.
Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for
Sjogren’s syndrome. Arthritis Rheum. 2004;51:601–4.
41. Porola P, Straub RH, Virkki LM, Konttinen YT, Nordstrom DC. Failure of oral
DHEA treatment to increase local salivary androgen outputs of female
patients with Sjogren’s syndrome. Scand J Rheumatol. 2011;40:387–90.
42. Lemp MA. Advances in understanding and managing dry eye disease.
Am J Ophthalmol. 2008;146:350–6.
43. Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of
moderate to severe dry eye: results of a physician survey. Trans Am
Ophthalmol Soc. 2009;107:205–10.
44. Graham JE, McGilligan VE, Berrar D, Leccisotti A, Moore JE, Bron AJ, et al.
Attitudes towards diagnostic tests and therapies for dry eye disease.
Ophthalmic Res. 2010;43:11–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sy et al. BMC Ophthalmology  (2015) 15:133 Page 6 of 6
